“Q2 was a fantastic quarter. As I mentioned in my letter, the company is hitting its stride as we approach our tenth anniversary.” (CEO)
“We saw another sequential improvement in adjusted EBITDA, which went from roughly negative $16 million last quarter to a negative $5.6 million this quarter. So we're approaching adjusted EBITDA breakeven.” (CEO)
“We increased our full year 2025 revenue guidance to $1.26 billion and maintained our adjusted EBITDA forecast of about $5 million for the year, which is roughly -- would be roughly $110 million improvement over last year.” (CEO)
“All in, the business is right where we want it to be, and we're making great progress.” (CEO)
Prepared Metrics
Metric
Value
Speaker/Context
总营收
3.146 亿美元
CEO, 同比增长 89.6%
基因组学营收
2.418 亿美元
CEO, 同比增长 115%
数据与服务营收
~7300 万美元
CEO, 同比增长 35.7%
Insights 营收增速
~41%
CEO, 数据与服务板块内
季度毛利润
1.95 亿美元
CEO, 同比增长 ~160%
调整后 EBITDA
-560 万美元
CEO, 上季度为 -1600 万美元
现金及有价证券
~2.9 亿美元
CEO, 季度末余额
可转换票据发行
7.5 亿美元
CEO, 票息 0.75%
2025 年全年营收指引
12.6 亿美元
CEO, 上调后
2025 年全年调整后 EBITDA 指引
~500 万美元
CEO, 维持
Q&A Batch (1-5 of 5)
Q1 — Daniel Gregory Brennan
Topic: Core Genomic volumes, Ambry performance, and Insights/Pathos growth drivers
Key points:
Significant sequential volume growth across entire oncology testing compendium (tissue and liquid), driven by sales force efficiency, territory realignment, and technology stack improvements.
Hereditary volumes (Ambry) significantly stronger than expected, with no near-term slowdown; growth from historic players shrinking market share and overall space tailwinds.
Insights business grew 40% in Q2; large deal signed for foundation model; management targets 25%-30% growth rate for data business (grew above that in Q2).
Mgmt stance: Bullish — management sees sustained momentum from initiatives paying off, hereditary sequencing volumes potentially larger than cancer sequencing, and data business with strong visibility.
Q2 — Yuko Oku
Topic: ASP cadence for xT to CDx migration and RNA sequencing features
Key points:
Question asks about ASP path toward migrating 40% of xT volume to CDx by year-end, and ASP drag from xM ramp.
Response (James Rogers) cut off; no specific numbers or guidance provided in the input.
Mgmt stance: Neutral — no data available in the input to assess stance.
Q3 — Eric P. Lefkofsky
Topic: RNA sequencing capabilities and future panel evolution
Key points:
Company has done whole transcriptome sequencing since lab opening, using targeted panel for DNA and whole transcriptome for RNA from FFP slides.
Panel reports expression levels on entire transcriptome, plus TCR profiling, BCR profiling, HLA typing, and other algorithms.
Future advancements likely on DNA side, migrating from targeted panel to whole genome sequencing over 5-10 years; targeted panels expected to largely disappear.
Mgmt stance: Bullish — positions whole transcriptome as comprehensive and pioneering, with clear long-term roadmap toward whole genome sequencing.
Q4 — Rachel Marie Vatnsdal Olson
Topic: Insights/trials bookings, pharma headwinds, and Pathos revenue trajectory
Key points:
Bookings super strong in Q2 due to AstraZeneca Pathos deal (April event); total contract value ahead of expectations for back half.
Clinical trial matching business not a large dollar driver currently (e.g., 10-30 patients per trial), but important for provider relationships (connected to >4,500 providers/institutions).
Pathos revenue ~$16 million in Q2; back half will see sequential slight step-up (no full quarter in Q2), with similar levels on a quarterly basis.
Mgmt stance: Bullish — no weakness from pharma headlines or biotech funding constraints; Pathos revenue stable with slight step-up.
Q5 — Michael Leonidovich Ryskin
Topic: Pharma partnership pipeline, competitive landscape, and investment priorities
Key points:
Pipeline continues super strong; only past market impact was biotech funding drying up in 2022 (long in rearview mirror).
No pressure from competitors in data/AI space; lost deals are due to clients not wanting to invest, not to competing products.
Adjusted EBITDA improvement driven by discipline; company still making significant investments in growth (Genomics, data, AI) and not optimizing for short term.
Mgmt stance: Bullish — healthy pipeline of very big deals, no competitive pressure, and disciplined investment approach to reach adjusted EBITDA and cash flow positive without starving growth.